The ED50 of DEX for Providing Sedation in Different Female Age Group

Guangzhou General Hospital of Guangzhou Military Command

Status and phase: Unknown; Phase 4

Conditions: Combined Spinal-epidural Anesthesia

Treatments: Drug: Dexmedetomidine B; Drug: Dexmedetomidine C; Drug: Dexmedetomidine A

Study type: Interventional

Funder types: Other

Identifiers

NCT02773017

DEX sedation

Details and patient eligibility

About

Dexmedetomidine(DEX) could provide dose-dependent sedation , analgesia , anti-anxiety and inhibition of sympathetic nerves and other effects. Because of its minimal impact on the respiratory , currently it was more and more widely used to sedate patients undergoing regional anesthesia.Many anesthetic pharmacokinetics and pharmacodynamics are often affected by age, and current studies with regard to the effects of age on dexmedetomidine pharmacodynamic are rare. This study was designed to explore the right DEX dose of different female Age of patients to produce suitable sedation.Dexmedetomidine be used in patients with combined spinal and epidural anesthesia for sedation,which is monitored by the Narcotrend,during the operation.The relation between Narcotrend index (NTI) and the depth of sedation for patients is also investigated.

Full description

90 patients scheduled for combined spinal epidural spinal anesthesia were included in one of three groups. In each group,determination of median effective (ED50) doses was performed by the Dixon up-and-down method, an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1 μg/kg in first three turning points and 0.05μg/kg in the last three turning points.Initial doses was 1.4μg/kg, .Sedative efficacy was defined as an OAA/S of ≤3,30 min after the beginning of drug administration.

Enrollment: 90 estimated patients

Sex: Female

Ages: 20 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. ASA Ⅰ ~ Ⅱ patient undergoing lower extremity surgery
2. Written informed consent from the patient or the relatives of the participating patient.
3. BMI:18.0～25.0kg/m2

Exclusion criteria

1. Mental illness can not match

2. epidural anesthesia contraindicated

3. People who have Slow-type arrhythmias

4. People who were language or hearing impaired

5. Sensory block reached to T8 or higher.

6. People who had lung infection or sleep apnea syndrome.

7. Pregnancy

8. Chronic renal failure

9. Alcohol or drug abuse

10. Already taking gabapentin, pregabalin, benzodiazepin or antidepression drug

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

Youth female group

Experimental group

Description:

patients in the Youth female group, aged 20\~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.

Treatment:

Drug: Dexmedetomidine A

Middle-aged female group

Experimental group

Description:

patients in the Middle-aged female group, aged 40\~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.

Treatment:

Drug: Dexmedetomidine B

Elderly female group

Experimental group

Description:

Patient in the elderly female group, aged 65\~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.

Treatment:

Drug: Dexmedetomidine C